[
    [
        {
            "time": "2020-03-11",
            "original_text": "SOHO中国称正与海外金融投资者洽谈 邮储银行获控股股东斥资逾25亿元增持A股",
            "features": {
                "keywords": [
                    "SOHO中国",
                    "邮储银行",
                    "海外金融投资者",
                    "洽谈",
                    "增持"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "房地产",
                    "银行"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "SOHO中国称正与海外金融投资者洽谈 邮储银行获控股股东斥资逾25亿元增持A股",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-03-11",
            "original_text": "复星医药“17复药01”回售申报数量为158.05万张",
            "features": {
                "keywords": [
                    "复星医药",
                    "17复药01",
                    "回售"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星医药“17复药01”回售申报数量为158.05万张",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-03-11",
            "original_text": "复星医药：Tenapanor片于治疗高磷血症的临床试验获批准",
            "features": {
                "keywords": [
                    "复星医药",
                    "Tenapanor片",
                    "高磷血症",
                    "临床试验"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药：Tenapanor片于治疗高磷血症的临床试验获批准",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 10
            }
        },
        {
            "time": "2020-03-12",
            "original_text": "A股头条之上市公司",
            "features": {
                "keywords": [
                    "A股",
                    "上市公司"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "A股头条之上市公司",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 3,
                "Impact": 2,
                "Duration": 2,
                "Entity_Density": 2,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 4,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-03-11",
            "original_text": "液态医用氧产能实现湖北省医疗机构全覆盖 和远气体预计全年受疫情影响可控",
            "features": {
                "keywords": [
                    "液态医用氧",
                    "和远气体",
                    "疫情",
                    "影响"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "化工"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "液态医用氧产能实现湖北省医疗机构全覆盖 和远气体预计全年受疫情影响可控",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-03-11",
            "original_text": "复星医药Tenapanor片获得III期临床试验通知",
            "features": {
                "keywords": [
                    "复星医药",
                    "Tenapanor片",
                    "III期临床试验"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药Tenapanor片获得III期临床试验通知",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "2020-03-11",
            "original_text": "复星医药：控股子公司Tenapanor片获临床试验通知书",
            "features": {
                "keywords": [
                    "复星医药",
                    "Tenapanor片",
                    "临床试验"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药：控股子公司Tenapanor片获临床试验通知书",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-03-11",
            "original_text": "复星医药：“17复药01”回售金额为人民币1.5805亿元，拟进行转售",
            "features": {
                "keywords": [
                    "复星医药",
                    "17复药01",
                    "回售",
                    "转售"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星医药：“17复药01”回售金额为人民币1.5805亿元，拟进行转售",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-03-11",
            "original_text": "复星医药：控股子公司获临床试验通知书",
            "features": {
                "keywords": [
                    "复星医药",
                    "临床试验"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药：控股子公司获临床试验通知书",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-03-11",
            "original_text": "复星医药：经一线化疗失败的晚期宫颈癌治疗方案启动II期临床研究",
            "features": {
                "keywords": [
                    "复星医药",
                    "晚期宫颈癌",
                    "临床研究"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药：经一线化疗失败的晚期宫颈癌治疗方案启动II期临床研究",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-03-15",
            "original_text": "大盘出现调整，全球产业链定价能力和内需驱动的医药细分龙头投资性价比凸显",
            "features": {
                "keywords": [
                    "大盘调整",
                    "全球产业链",
                    "医药细分龙头",
                    "投资性价比"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "大盘出现调整，全球产业链定价能力和内需驱动的医药细分龙头投资性价比凸显",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]